CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella, a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will participate in the following upcoming investor conferences:
- 25th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona, with a presentation on November 7, 2016, at 1:30 p.m. MST
- Stifel 2016 Healthcare Conference in New York, NY, with a presentation on November 15, 2016 at 11:45 a.m. EST
About Axcella
Axcella is pioneering revolutionary new
medicines with a focus on amino acid homeostasis. The company has
discovered more than 2,000 diseases with amino acid imbalances and
developed a systems pharmacology approach to restore health at the
cellular level. Axcella’s proprietary platform is clinically validated
across several indication areas, with clinical-stage candidates in
metabolic (liver, muscle) and neurodegenerative conditions. Axcella is
led by a team with a strong track record of leaving a lasting impact on
the therapeutic landscape through the development of novel products. The
company was founded by VentureLabs, the Innovation Foundry at Flagship
Ventures, and has received additional funding from Fidelity Research &
Management Group, Gurnet Point Capital and Nestlé Health Science.
Axcella is based in Cambridge, Mass. For more information, visit www.axcellahealth.com.
